Compositions Of Glp-1 Peptides And Preparation Thereof

Patent No. EP2827885 (titled "Compositions Of Glp-1 Peptides And Preparation Thereof") was filed by Novo Nordisk on Mar 15, 2013. The application was issued on Aug 15, 2018.

Patent Summary

A pharmaceutical composition for oral delivery of GLP-1 peptides, comprising two types of granules: a first type containing a delivery agent (SNAC) and a second type containing the GLP-1 peptide. The composition is prepared by dry granulation of the individual components, followed by mixing and compression into tablets. The delivery agent is released simultaneously with or faster than the GLP-1 peptide, enhancing bioavailability.

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GALENICUM HEALTH SLUMay 15, 2019TORREJON NIETO
GENERICS UKMay 15, 2019TER MEER STEINMEISTER & PARTNER
HEXALMay 15, 2019MAIWALD
TEVA PHARMACEUTICALSMay 13, 2019VON KAUFFMANN

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2827885

NOVO NORDISK
Application Number
EP13709231A
Filing Date
Mar 15, 2013
Status
Revoked
Nov 22, 2024
Publication Date
Aug 15, 2018